01—Abstract
Summary
Summary of the 10-K filed February 18, 2022. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories' 2021 10-K filing reveals a robust performance, largely driven by significant growth in its Diagnostics segment, primarily fueled by COVID-19 testing solutions.
Despite global supply chain challenges and inflationary pressures, the company demonstrated strong overall sales growth. The Medical Devices segment also showed a healthy rebound with double-digit growth in key divisions.
The Established Pharmaceuticals and Nutritional Products segments contributed steady growth, though the latter faced some headwinds in international pediatric nutrition. Abbott continues to invest in research and development across its segments, aiming for sustainable growth and market leadership.
02—Key points
Key Highlights
- Abbott Laboratories reported substantial revenue growth in 2021, largely propelled by a significant surge in its Diagnostics segment, driven by COVID-19 testing products like BinaxNOW and Panbio.
- The Medical Devices segment experienced strong recovery, with double-digit growth in Diabetes Care, Structural Heart, and Electrophysiology, signaling a rebound in elective procedures.
- The company maintained a strong financial position, with substantial cash and cash equivalents, and continued its commitment to returning value to shareholders through a significant increase in dividends declared and share repurchases.
- Abbott is actively managing global supply chain challenges and inflationary pressures, implementing strategies to mitigate the impact of rising costs through price increases and efficiency initiatives.
- Research and development remains a key focus, with ongoing investment in innovation across all segments, including new product introductions and enhancements for its FreeStyle Libre diabetes monitoring system and structural heart devices.
- The company's global presence is a significant strength, with international sales comprising approximately 61% of total net sales, demonstrating resilience and diversification.
- Abbott declared a 19% increase in dividends per share in 2021 compared to 2020, reflecting confidence in its financial performance and commitment to shareholder returns.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2021, Abbott Laboratories kept $0.16.
- Revenue$43.08B100.0%
- Cost of revenue−$18.54B43.0%
- Gross profit$24.54B57.0%
- Operating costs−$16.11B37.4%
- Operating income$8.43B19.6%
- Interest, other & tax−$1.35B3.1%
- Net income$7.07B16.4%
Where FY2021 revenue went
$43.08B- Cost of revenue: $18.54B, 43% of revenue
- SG&A: $11.32B, 26% of revenue
- Net income: $7.07B, 16% of revenue
- R&D: $2.74B, 6.4% of revenue
- Other operating costs: $2.05B, 4.8% of revenue
- Interest, other & tax: $1.35B, 3.1% of revenue
Kept 16% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2021filed February 18, 2022Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $43.08B$34.61B | +24.5% |
| Cost of Revenue | $18.54B$15.00B | +23.6% |
| Gross Profit | $24.54B$19.61B | +25.2% |
| R&D Expenses | $2.74B$2.42B | +13.3% |
| SG&A Expenses | $11.32B$9.70B | +16.8% |
| Operating Expenses | $34.65B$29.25B | +18.5% |
| Operating Income | $8.43B$5.36B | +57.3% |
| Interest Expense | $533.00M$546.00M | −2.4% |
| Net Income | $7.07B$4.50B | +57.3% |
| EPS (Basic) | $3.97$2.52 | +57.5% |
| EPS (Diluted) | $3.94$2.50 | +57.6% |
| Shares Outstanding (Basic) | 1.77B1.77B | +0.1% |
| Shares Outstanding (Diluted) | 1.79B1.79B | +0.2% |
05—Questions
Frequently Asked Questions
What were the main drivers of Abbott's revenue growth in 2021?
The primary driver of Abbott's revenue growth in 2021 was the strong performance of its Diagnostics segment, particularly the demand for its COVID-19 testing solutions, such as the BinaxNOW and Panbio rapid antigen tests. The Medical Devices segment also contributed significantly with a rebound in sales driven by increased procedure volumes and strong performance in key areas like Diabetes Care and Structural Heart.
How is Abbott managing supply chain disruptions and inflationary pressures?
Abbott is actively managing supply chain challenges and inflationary pressures by implementing price increases in certain businesses and focusing on gross margin improvement initiatives. While the company experienced some availability issues with materials and components, it has managed these challenges without significant supply disruptions to date. Abbott expects these inflationary pressures to continue but aims to mitigate their impact through these strategic actions.
What is Abbott's strategy for future growth?
Abbott's strategy for future growth involves continued investment in its key segments: Diagnostics (focusing on the Alinity suite), Medical Devices (expanding market position across various businesses), Nutritionals (driving global growth and introducing line extensions), and Established Pharmaceuticals (growing its portfolio in emerging markets). The company also maintains a strong commitment to research and development to drive innovation and maintain a competitive edge.
How did the COVID-19 pandemic impact Abbott's different business segments?
The COVID-19 pandemic had varied impacts. The Diagnostics segment saw significant sales increases due to COVID-19 testing. Medical Devices experienced initial declines in procedure-dependent businesses due to the pandemic but saw a strong recovery in 2021. The Established Pharmaceutical Products segment was also affected in emerging markets but recovered in 2021. The Nutritional and Diabetes Care businesses were the least impacted.
06—Continue